Drug Discovery Integration
Pelago Bioscience acquires RG Discovery, forming an integrated drug discovery partner.
Pelago Bioscience has acquired RG Discovery, creating a single drug discovery partner that handles both chemistry and biology under one roof. The deal unites Pelago's CETSA® technology — a method for measuring how drugs bind to targets inside living cells — with RG Discovery's medicinal chemistry and custom compound synthesis, according to Financial Post.
The combined company aims to cut the time it takes drug teams to move from finding a promising molecule to refining it for clinical use. Instead of passing work between separate biology and chemistry firms, clients now get one partner that designs, builds, and tests compounds in a continuous loop, Financial Post reported.
What CETSA® Does and Why It Matters
CETSA® stands for Cellular Thermal Shift Assay. In plain terms, it measures whether a drug is actually grabbing its target protein inside a real, living cell — not just in a test tube. This matters because many drug candidates look promising in lab dishes but fail when tested in living systems. Pelago built its entire business around this technology, which has been cited in over 400 peer-reviewed studies.
By pairing that biological readout with RG Discovery's team of PhD-level chemists, Pelago can now close what CEO Michael Dabrowski calls a critical gap. "By bringing RG Discovery into the Pelago family, we are closing the loop between designing a molecule and seeing how it actually behaves in a living cell," Dabrowski said. "Chemistry and biology happen simultaneously."
The Old 'Relay Race' Model Was Costing Drug Makers Time
Traditional drug discovery worked like a relay race. A biology firm would find a target, hand it to a chemistry firm to build molecules, then wait for results before repeating the cycle. Each handoff burned time. The average journey from hit identification to a refined lead compound takes 18 to 24 months under fragmented models, with coordination delays eating up roughly 30% of that window.
RG Discovery's Dr. Roland Goldberg said the integration solves a long-standing frustration. "Our chemistry team has always sought faster biological feedback to refine our designs," he said. "Joining Pelago gives us immediate access to the most sophisticated target engagement data available, allowing us to pivot design strategies in days rather than months."
One Company, Three Countries, and a Stronger European Pipeline
The merger brings Pelago's total headcount to over 120 employees spread across Sweden, Germany, and the United States. RG Discovery adds more than 30 PhD medicinal chemists to that team, along with a library of proprietary and custom-synthesized compounds. The combined operation links chemistry labs in Germany with Pelago's biology hubs in Stockholm and the U.S., strengthening Europe's drug discovery corridor, according to Edmonton Examiner.
Integrated drug programs historically reach Phase I clinical trials at a 20% higher rate than fragmented ones, according to industry benchmarking data. Industry experts estimate that tighter design-make-test-analyze cycles could cut lead optimization time by 25% to 40%, potentially adding significant speed to early-stage pipelines for biotech and pharma clients alike.
Virtual Biotechs and Big Pharma Both Stand to Benefit
For "virtual" biotechs — small companies that outsource most of their science — managing separate biology and chemistry vendors adds cost and complexity. A single partner simplifies contracts, aligns data formats, and reduces the back-and-forth that slows programs down. Venture capital investors have reacted positively, seeing the arrangement as a way to accelerate the timeline between funding and clinical proof-of-concept.
Larger pharmaceutical companies gain a different advantage: procurement simplicity and tighter data integrity. When one firm controls every step from synthesis to cellular testing, the chain of evidence for a compound stays intact. Pelago's acquisition follows a broader CRO trend set by firms like Charles River Laboratories and WuXi AppTec, but it is the first to center that integration specifically on CETSA® target engagement, according to Sudbury Star.
Sentiment
NeutralPublishers
7
Articles
7
Reach
7
